Chime Biologics and Mabgeek Achieve PPQ Milestone for MG-K10, Advancing Atopic Dermatitis and Asthma Therapies
Key Insights
Chime Biologics (search) and Mabgeek (search) completed Process Performance Qualification (PPQ) for MG-K10, a humanized anti-IL-4Rα (search) monoclonal antibody, crucial for regulatory compliance and manufacturing validation.
MG-K10 targets Th2-mediated inflammatory diseases like atopic dermatitis (search) and asthma (search), with Phase III clinical trials underway, and is designed for once-monthly dosing.
The collaboration focuses on commercial manufacturing and CMC development to accelerate MG-K10's commercialization in American and European markets, emphasizing strong efficacy and patient adherence.
Chime Biologics (search) and Mabgeek (search) have announced the successful completion of Process Performance Qualification (PPQ) for MG-K10, a humanized anti-IL-4Rα (search) monoclonal antibody. This achievement marks a significant step forward in the development of a novel therapeutic for Th2-mediated inflammatory diseases, including moderate-to-severe atopic dermatitis (search) (AD) and asthma (search). The collaboration aims to bring this innovative treatment to the American and European markets.
The partnership between Chime Biologics (search) and Mabgeek (search), initiated in 2022, centers on the commercial manufacturing of cGMP 2000L drug substance, late-stage chemistry, manufacturing, and controls (CMC) development, and biologics license application (BLA) support for MG-K10. This collaboration leverages Mabgeek's expertise in monoclonal antibody innovation and Chime Biologics' robust CMC processes to accelerate the commercialization of MG-K10 while adhering to global quality standards and regulatory requirements.
MG-K10: A Novel IL-4Rα Targeting Antibody
MG-K10 is a long-acting humanized mAb targeting IL-4Rα (search), designed for potential treatment of various Th2-related diseases, including atopic dermatitis (search), asthma (search), rhinosinusitis (search), prurigo nodularis (search), esophagitis (search), and COPD (search). Phase II clinical results in AD and asthma have indicated that MG-K10 has the potential to be a best-in-class therapy. In a Phase II trial for moderate-to-severe AD, MG-K10 significantly improved patients' clinical signs and quality of life. Similarly, in a Phase II trial for moderate-to-severe asthma, MG-K10 demonstrated significant improvements in lung function and clinical symptoms. Notably, MG-K10 is administered once every four weeks (Q4W), potentially improving patient adherence compared to other anti-IL-4Rα therapeutics requiring more frequent dosing (Q2W).
Clinical Development and Market Potential
MG-K10 is currently in Phase III clinical trials for atopic dermatitis (search), asthma (search), and prurigo nodularis (search). The successful PPQ validates the robust manufacturing standards and is crucial for regulatory compliance, paving the way for potential market entry in the United States and Europe. The strategic focus on these markets underscores the commitment to addressing unmet clinical needs in allergic inflammatory and autoimmune diseases.
"We are delighted with the successful completion of MG-K10’s PPQ," said Dr. Jimmy Wei, President of Chime Biologics (search). "This achievement marks a significant milestone in our partnership and signals its immense potential in the global market. Through our partnership with Mabgeek (search), we are advancing therapeutic innovation to accelerate the commercialization of MG-K10, ensuring patients worldwide receive transformative care sooner."
Dr. Chenghai Zhang, CEO of Mabgeek (search), added, "The successful PPQ for our pioneering MG-K10 antibody is a testament to the power of collaboration between us, and we are confident in entering the American and European markets, leveraging our strong innovation capabilities and commitment to meeting unmet clinical needs in allergic inflammatory diseases and autoimmune diseases."